High-Throughput Screening for Allosteric Modulators of GPCRs

Part of the Methods in Molecular Biology book series (MIMB, volume 1335)


The continued evolution of our understanding of G protein-coupled receptor (GPCR) signaling has revealed new opportunities for drug discovery. Specifically, biased agonism at GPCRs and allosteric modulation of GPCRs both represent emerging areas of GPCR biology that hold promise for the development of novel GPCR-targeted therapeutics that may provide greater therapeutic efficacy and/or improved side-effect profiles. To obtain initial chemical leads, high-throughput screening (HTS) of a large compound library for the desired activity is often deployed during the early stages of a discovery program. The identification of allosteric modulators, in particular, poses significant challenges for HTS. We describe several HTS protocols designed for the identification of GPCR ligands, with a particular focus on the identification of allosteric modulators.

Key words

G protein-coupled receptor Allosteric HTS NAM PAM SAM Calcium flux FLIPR FDSS 


  1. 1.
    Filmore D (2004) It’s a GPCR world. Modern Drug Discov (Am Chem Soc) 7:24–28Google Scholar
  2. 2.
    Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993–996PubMedCrossRefGoogle Scholar
  3. 3.
    Kostenis E, Waelbroeck M, Milligan G (2005) Techniques: Promiscuous Gα proteins in basic research and drug discovery. Trends Pharmacol Sci 26:595–602PubMedCrossRefGoogle Scholar
  4. 4.
    Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323–374PubMedCrossRefGoogle Scholar
  5. 5.
    May LT, Leach K, Sexton PM et al (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1–51PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang JH, Chung TD, Oldenberg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73PubMedCrossRefGoogle Scholar
  7. 7.
    Burford NT, Bertekap RL Jr, Banks M et al (2011) Hit identification practices for positive allosteric modulators of G protein-coupled receptors: The need for multiple-mode screening approaches in dynamic Ca2+ flux assays. Int Drug Discov 6(1):28–33Google Scholar
  8. 8.
    Sharma S, Rodriguez AL, Conn PJ et al (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg Med Chem Lett 18:4098–4101PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Jacoby E, Bouhelal R, Gerspacher M et al (2006) The 7 TM G-protein-coupled receptor target family. ChemMedChem 1:761–782PubMedCrossRefGoogle Scholar
  10. 10.
    Rodriguez AL, Grier MD, Jones CK et al (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity an in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78:1105–1123PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Noblin D, Bertekap RL Jr, Burford NT et al (2012) Development of a high-throughput calcium flux assay for identification of all ligand types including positive, negative, and silent allosteric modulators for G protein-coupled receptors. Assay Drug Dev Technol 10:457–467PubMedCrossRefGoogle Scholar
  12. 12.
    Burford NT, Watson J, Bertekap R et al (2011) Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 81:691–702PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Lead Discovery, Bristol-Myers Squibb CompanyWallingfordUSA

Personalised recommendations